NEW YORK — Fujitsu Laboratories and Aichi Cancer Center announced on Friday that they have signed an agreement to develop technologies for cancer genome data analysis.
The partners said they will use genomic and clinical cancer data, primarily on solid tumors, to develop artificial intelligence-based technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.
Fujitisu Laboratories, a subsidiary of Japanese technology firm Fujitsu, will oversee database construction and the integration of clinical and genomic profiles, as well as the development of technologies for patient diagnosis and drug selection. Nagoya, Japan-based Aichi will be responsible for providing patient-specific genomic and medical data, offering guidance on data interpretation and treatment selection for different cancer types, and verifying technologies developed under the collaboration in clinical settings.
Fujitsu Laboratories and Aichi said that they intend to roll out the tools developed under their alliance to certain hospitals in Japan and collect patient data to improve the underlying technologies.
Additional terms were not disclosed.